Opportunity to Acquire - Oral and Topical Dosage Manufacturing Facility
Commissioned in Sep 2018, the manufacturing facility is located in RIICO Industrial Area, Keshwana, Rajasthan, India. The facility was set up with a capex of USD 10 million.
Facility is approved by local FDA authority
The facility has oral solid dosage (tablets, capsules, dry syrup) and ointment facility, with a scope to set up injectables and eye drop section for general category
Therapeutic segments: Antihistamine, Antiretroviral, Antiulcer, Antispasmodic, Gastroenterology, Cardiovascular, Antifungal, Analgesics, Antibiotics and Genito Urinary System
Exports contribute more than 75% of the revenue, with Antiretroviral products and molecules in cephalosporin and macrolides group of antibiotics mainly contributing to company’s exports
Revenue from operations in FY19 was USD 4 million, with ~49% gross margins. At peak, revenues stood at USD 7 million in FY16
Sign in or register to add a comment.
Add a Comment
Welcome to the MGI M&A Marketplace!
Investment Opportunity - Women’s Institute of Infertility and Gynaec Endoscopic Surgery
Opportunity to acquire an Italian profitable metal products company
Opportunity to acquire UK Midlands Electronics Company
API Company based out of Gujarat, India available for acquisition
HOW TO USE THIS MARKETPLACE
Terms of Service and legal disclaimers
Useful tips on viewing and editing
Created with PlushForums
© 2020 MGI Worldwide with CPAAI M&A Marketplace